DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in Polycystic Ovary Syndrome

Information source: Mansoura University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Polycystic Ovary Syndrome

Intervention: Coenzyme Q10 (Drug); clomiphene citrate (Drug)

Phase: N/A

Status: Completed

Sponsored by: Mansoura University

Summary

Objective of the study was to evaluate the effect of combination of oral Coenzyme Q10 (CoQ10), with clomiphene citrate (CC) for ovulation induction in CC-resistant polycystic ovary syndrome (PCOS).In a prospective controlled randomized trial performed in a university hospital and private practice setting. One hundred ten infertile women with PCOS resistant to CC were randomized to either combined CC/CoQ10 (51 patients, 82 cycles) or CC 150 mg/day alone (50 patients, 71 cycles) for ovulation induction in patients with CC-resistant PCOS. Main outcome measures: Number of follicles, serum E2, serum P, endometrial thickness, pregnancy rate (PR) and miscarriage rate.

Clinical Details

Official title: Combined Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in CC-resistant Patients With Polycystic Ovary Syndrome

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Primary outcome: Number of ovulating patients

Secondary outcome: Number of pregnancies

Detailed description: No more details

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Diagnosis of PCOS based on the revised 2003 consensus on diagnostic criteria and

long-term health risks related to PCOS (2003).

- All women were previously treated with 100 mg of CC daily for 5 days per cycle, for

two to three cycles with persistent anovulation or ovulate with very thin endometrium <5 mm at the time of hCG administration Exclusion Criteria:

- patients with hyperprolactinaemia,

- hypercorticism and

- thyroid dysfunction.

- patients receiving medications as cholesterol lowering drugs, as statins,

beta-blockers, and tricyclic antidepressants

Locations and Contacts

Mansoura University Hospitals, Mansoura, Dakahlia 35111, Egypt
Additional Information

Starting date: January 2010
Last updated: July 29, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017